meglitinides
glinides

Meglitinides (glinides) are a class of drugs used treat diabetes type 2.

Its use with insulin, meglitinides, and alpha-glucosidase inhibitors has not been studied.

Meglitinides help the pancreas produce insulin and are often called "short-acting secretagogues."

Repaglinide is an antidiabetic drug in the class of medications known as meglitinides, and was invented in 1983.

Meglitinides are similar to sulfonylureas.

Meglitinides (repaglinide and nateglinide): taken to stimulate the cells found in the pancreas to release insulin.

Biguanides do not affect the output of insulin, unlike other hypoglycemic agents such as sulfonylureas and meglitinides.

One of their advantages over older insulin secretagogues, such as sulfonylureas or meglitinides, is that they have a lower risk of causing hypoglycemia.

Evidence also supports thiazolidinediones but there are safety concerns, and data on newer agents such as GLP-1 receptor agonists, DPP4 inhibitors or meglitinides are lacking.

On June 17, 2010, the Committee removed the usage of glinides from general prescription guidelines for the reduction of human glucose levels.

Those are drugs, such as sulfonylureas and glinides, which stimulate the pancreas to secrete more insulin or raise circulating levels of insulin.

Medical condition 'Managed by tablets which carry a risk of inducing hypoglycaemia (this includes sulphonylureas and glinides)' wording revised for Group 1, ODL in first paragraph.